Investors are always looking for stocks that are poised to beat at earnings season
Five Prime Therapeutics, Inc.
FPRX
may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Five Prime Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for FPRX in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 6 cents per share for FPRX, compared to a broader Zacks Consensus Estimate of a loss of 50 cents per share. This suggests that analysts have very recently bumped up their estimates for FPRX, giving the stock a Zacks Earnings ESP of +88.00% heading into earnings season.
Five Prime Therapeutics, Inc. Price and EPS Surprise
Five Prime Therapeutics, Inc. price-eps-surprise
|
Five Prime Therapeutics, Inc. Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more
Top Earnings ESP stocks here
).
Given that FPRX has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Five Prime Therapeutics, and that a beat might be in the cards for the upcoming report.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report